Eve Speicher
Primary Care · Newton, NJNPI 1811477714
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,259, 2.6 times the $481 reported in 2021. Among primary care clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$693
- AstraZeneca$385
- Pfizer$328
- Lilly USA, LLC$295
- AbbVie$257
- GSK$250
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,35397%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$3,453 in reported general payments places this provider in the 90th percentile of 330 primary care providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Venlafaxine Hcl ErVenlafaxine Hcl | 21 | $1,731 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 11 | $1,404 |
| Montelukast Sodium | 26 | $819 |
| Atorvastatin Calcium | 76 | $799 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $750 |
| Valsartan | 17 | $657 |
| Levothyroxine Sodium | 57 | $549 |
| Gabapentin | 21 | $527 |
| Pantoprazole Sodium | 34 | $448 |
| Fluticasone Propionate | 31 | $440 |
| Cyclobenzaprine Hcl | 13 | $409 |
| Omeprazole | 38 | $385 |
| Amlodipine Besylate | 53 | $359 |
| Simvastatin | 25 | $357 |
| Buspirone Hcl | 12 | $340 |
Paid to pharmacies, not to this prescriber.
Other primary care in Newton
- Michael Zito GovertNeptune$61K
- Roseann BenantiEnglewood$24K
- Marcelo MarinEnglewood$17K
- Jennifer EdwardsPrinceton$14K
- Mary Grace TolentinoJersey City$9K
- Kevin Robert ReyladoNorth Arlington$8K
- Carlo SebelloJersey City$8K
- Karam WehbehPaterson$7K
- Shazam BacchusNewark$7K
- Anna NievesBasking Ridge$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.